Biopharma Targets Rise, Fintech Gets Clipped

Analyst target prices moved broadly higher on Saturday. Healthcare and real estate names led the upgrades. Fintech and media drew the cuts.

AbbVie saw the biggest consensus target lift of the day. The average price target climbed to $273.86, up from $273.39. The pharma giant carries a market cap of $431 billion. Short interest sits at just 1.3% of free float — bears have little appetite here.

Amgen also gained ground with analysts. The consensus target rose to $378.31 from $374.69. That is a $3.62 gain per share in expected value. At $219 billion market cap, Amgen remains a consensus favourite with 16 hold and 4 buy ratings.

Fidelity National Information Services took a hit. The consensus target dropped to $51.09 from $52.45. The fintech firm has struggled to define its post-Worldpay identity. Short interest sits at 4.1% of free float.

Paramount Skydance also saw its target trimmed to $9.81 from $10.12. The media merger stock has the highest short interest of the group at 9.7% of free float. Analysts hold 7 buy, 10 hold, and 3 sell ratings — a divided picture. The tight availability of shares to borrow suggests some positioning risk for shorts.

Motorola Solutions bucked the trend with an upgrade in target to $522.73. Analysts remain mostly bearish with 12 sell ratings, but the target move signals modest optimism.